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Abstract
Background: Prevention of a possible avian influenza pandemic necessitates the development of
rapid diagnostic tests and the eventual production of a vaccine.
Results: For vaccine production, hemagglutinin (HA1) from avian influenza H5N1 was expressed
from a recombinant baculovirus. Recombinant HA1 was expressed in monolayer or suspension
culture insect cells by infection with the recombinant baculovirus. The yield of rHA1 from the
suspension culture was 68 mg/l, compared to 6 mg/l from the monolayer culture. Immunization of
guinea pigs with 50 µg of rHA1 yielded hemagglutinin inhibition and virus neutralization titers of
1:160 after two times vaccination with rHA1 protein.
Conclusion: Thus, the production of rHA1 using an insect suspension cell system provides a
promising basis for economical production of a H5 antigen.
Background
Influenza A viruses have a segmented genome of single-
stranded negative-sense RNA and belong to the family
Orthomyxoviridae [1]. They have been isolated from a vari-
ety of animals, including humans, pigs, horses, sea mam-
mals, and birds [2]. There are 16 subtypes of influenza
virus A, among them the highly pathogenic avian H5N1
viruses which caused 18 confirmed infections and six
deaths in Hong Kong in 1997. This virus can apparently
be transmitted directly from birds to humans with no
intermediate mammalian host [3]. Infection of poultry
with highly pathogenic avian influenza virus can be dev-
astating in terms of flock morbidity and mortality, eco-
nomic loss and social disruption [4]. Swayne et al. [5]
suggested that vaccination has the potential to reduce
environmental contamination with avian influenza virus
and prevent subsequent bird-to-bird transmission [5]. In
order to prevent spread of influenza viruses, emphasis
must be placed on biosecurity and flock management
practices, the development of rapid diagnostics [4] and
vaccine production [6]. Current influenza vaccines
include a subunit vaccine [7-10], attenuated vaccine
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[11,12], DNA vaccine [13] and inactivated influenza vac-
cine [14], with the latter being the most widely used on a
commercial scale [6].
Current inactivated vaccines production requires large
numbers of embryonated chicken eggs [9]. The major
problems for production of this type of vaccine are the
requirements for high-level biocontainment facilities, and
in some cases, an inability to obtain high yields of virus in
embryonated chicken eggs [6]. The yield of total viral pro-
tein from the 10-day-old chicken embryos is typically 20–
40 mg/200 eggs [15]. Therefore large scale preparation of
inactivated vaccine by this method is not feasible.
Subunit vaccines, recombinant hemagglutinin and neu-
raminidase [7-10] may be an attractive alternative to the
inactivated vaccine, although none are currently in use as
commercial vaccines. The preparation of such vaccines is
obviously safer than for an inactivated vaccine and prepa-
ration of candidate subunit vaccines is simple [16]. More-
over, subunit vaccines do not generate antibody responses
to internal influenza viral proteins and thus allow distinc-
tion between vaccinated and infected birds [8].
Hemagglutinin protein is the receptor-binding and mem-
brane fusion glycoprotein of influenza virus and the target
for infectivity-neutralizing antibodies [17,18]. The entire
hemagglutinin protein (HA) from the H5N1 is composed
of 568 amino acids, with a molecular weight of 56 kDa.
The HA molecule consists of HA1 and HA2 subunits, with
the HA1 subunit mediating initial contact with the cell
membrane and HA2 being responsible for membrane
fusion [17].
The recombinant hemagglutinin protein can be produced
in different ways such as expression of hemagglutinin pro-
tein in the insect cell system [8-10,16,19,20] or in the
recombinant baculovirus express in insect larvae [21]. Pre-
vious baculovirus/insect cell systems have been used to
express hemagglutinin genes isolated from avian influ-
enza subtypes. However, a protein band corresponding to
rHA1 from baculovirus infected cells was not observed by
SDS/PAGE of total cell protein. This could have been due
to a low level of expression or alternatively incorrect glyc-
osylation of the polypeptide in insect cells [19].
The recombinant baculovirus/insect cell system can be
carried out under monolayer and suspension culture. In
this research the HA1 gene from avian influenza virus
H5N1 encoded recombinant baculovirus was constructed
and infected into insect cells under different culture meth-
ods and condition. The expression level of recombinant
hemagglutinin protein in baculovirus/insect cell system
was compared. Guinea pigs were immunized with recom-
binant hemagglutinin protein in order to evaluate its
immunogenicity.
Results and discussion
Expression of recombinant hemagglutinin in insect cells 
under monolayer and suspension culture conditions
A recombinant baculovirus carrying the HA1 gene of
avian influenza A/goose/Guangdong/97 (H5N1) was
constructed and propagated in Sf9 cells. After 4 genera-
tions, the virus stock was collected and the expression
level of recombinant hemagglutinin protein was deter-
mined under monolayer and suspension culture condi-
tions.
The Sf9 cells were infected with the recombinant baculo-
virus and cultured in 175 cm2 flasks for monolayer culture
and in 500 ml baffled glass flasks for suspension culture.
The monolayer culture was incubated in the incubator
and the suspension culture was incubated in the shaking
incubator for 0, 63, 87, 111 and 135 h. SDS-PAGE and
immunoblot analysis of baculovirus infected Sf9 cells
from monolayer and suspension cultures revealed an
obvious difference in the amount of the 35 kDa rHA1 pro-
tein between the different cultures, with a far yield being
obtained from the suspension culture than the monolayer
culture after a 111 h incubation (Figure 1, compare lanes
1 and 2, and lanes 3 and 4). Confocal imaging of the
rHA1-expressing Sf9 cells using a H5 influenza-specific
SDS-PAGE and immunoblot analysis of rHA1 protein  expressed in a baculovirus/insect cell system under monol- ayer (lanes 1 and 3) and suspension (lanes 2 and 4) culture  conditions Figure 1
SDS-PAGE and immunoblot analysis of rHA1 protein 
expressed in a baculovirus/insect cell system under monol-
ayer (lanes 1 and 3) and suspension (lanes 2 and 4) culture 
conditions. Values on the left indicate molecular weights of 
the marker protein (lane M). The rHA1 was detected by 
immunoblotting with rabbit anti-H5N1 serum.BMC Microbiology 2006, 6:16 http://www.biomedcentral.com/1471-2180/6/16
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monoclonal antibody indicated that the protein was
localized primarily in the cytoplasmic space (Figure 2).
Under monolayer culture conditions, a cell density of 109
cells/l yielded 6 mg/l of hemagglutinin protein (Figure
3A). In contrast, the suspension cell culture could be
grown in reusable 500 ml baffled glass flasks with approx-
imately the same cell density yielded almost 68 mg/l of
rHA1 (Figure 3B). This may be due to a reduced efficiency
of baculovirus entry into the Sf9 cells and lowered cell
substrate uptake in the monolayer culture, as suggested in
the Dee and Shuler [22] mathematical treatment of the
diffusion-limited attachment rate in suspension and
monolayer cultures.
Influence of harvesting time on hemagglutinin expression 
in suspension culture
The Sf9 medium contains a mixture of sugars: glucose,
fructose and sucrose. Glucose concentration in the culture
remained above 10 g/l at the end of fermentation, indicat-
ing that the carbon source was not a limiting factor in this
medium (Figure 3B). Suspension cultures were incubated
in a shaker incubator, so optimization of harvesting time
could be performed with ease in the shortest possible
time. The results from the suspension culture are pre-
sented in Figure 3B, illustrating the cell growth pattern
after infection and the kinetics of hemagglutinin protein
in the infected Sf9 cells. There was an initial increase in the
volumetric yield of hemagglutinin protein at the peak cell
density, the maximum viable cell density postinfection.
The observed hemagglutinin protein was 68 mg/l at 111 h
post infection. At the very late phase (138 h) the yield of
hemagglutinin protein in the cell decreased. The resultant
secreted protein in the medium was 259 mg/l after 138 h
compared with 174 mg/l at 111 h. This may be due to the
lysis of some cells releasing occluded virus and some
intracellular protein into the extracellular fluid. Possee
[19] also reported that HA activity peaked at 24 h and
decreased at 48 h postinfection in a similar expression sys-
tem. In that study it was assumed that this decline pre-
sumably reflected cell lysis and subsequent degradation of
HA. According to these results, appropriate harvesting
time of baculovirus infected Sf9 cells was an important
factor in obtaining a high yield of hemagglutinin.
Sugiura et al. [21] obtained 0.4–4 µg/larvae of purified
hemagglutinin protein from the recombinant baculovirus
infected in silkworm larvae. Possee [19] observed the
hemagglutinin presented in the plasma membrane of the
infected cells and HA activity of 6.5 × 102 HAU/106 cells
was reached at peak infection of recombinant baculovirus
to the S. frugiperda cells. In this study a yield of 77 µg/106
cells was obtained from the recombinant baculovirus
infected in the Sf9 cells. This may be due to the expression
of hemagglutinin protein localized in the cytoplasm of
infected cells.
Purification of hemagglutinin protein from the 
recombinant baculovirus infected Sf9 cell
The expressed hemagglutinin protein was partially puri-
fied with the lysis buffer incorporated with 1% NP-40.
Samples were taken from each purification step and ana-
lyzed by SDS-PAGE and immunoblotting (Figure 4). The
majority of rHA1 presented as insoluble material in the
pellet as evidenced by immunoblot analysis. Therefore
recombinant protein is expressed as a dimeric species that
is present in both insoluble and free forms in the infected
Sf9 cells. When the cell lysis experiment was repeated
under various pH conditions, no additional extraction
was achieved and the protein of interest remained insolu-
ble.
Immunogenicity of recombinant hemagglutinin subunits in 
guinea pigs
There are numerous studies of the immune response to
baculovirus-expressed recombinant hemagglutinin
expressed in mice [9,23], chickens [8], horses [21] and
humans [16,20]. Doses of 15–135 µg of rHA1 protein are
typically required to induce the same level of immunity in
humans as that achieved with a standard dose of inacti-
vated influenza vaccine containing 15 µg of HA antigen
Confocal imaging of recombinant baculovirus infected Sf9 cell  (A and B) and uninfected Sf9 cell (C and D) Figure 2
Confocal imaging of recombinant baculovirus infected Sf9 cell 
(A and B) and uninfected Sf9 cell (C and D). DAPI was used 
to stain cell nuclei and monoclonal antibody specific to HA1 
of avian influenza H5 was used to localize rHA1 in recom-
binant baculovirus infected cells and uninfected cells.BMC Microbiology 2006, 6:16 http://www.biomedcentral.com/1471-2180/6/16
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[16]. Jones et al. [23] reported that higher doses of subunit
vaccine were needed to induce responses comparable to
those elicited by current licensed egg-derived, detergent-
split influenza vaccines.
In order to study the immunogenicity of the recombinant
hemagglutinin obtained from the suspension culture,
guinea pigs were immunized with rHA1 as insoluble and
detergent-solubilized protein and the immune response
measured by hemagglutinin inhibition, HI and virus neu-
tralization assays. The antibody response to these proteins
is shown in Table 1. Neutralizing antibody responses to a
titer of 1:160 and an HI titre of 1:160 were obtained after
two vaccinations with 50 µg of insoluble rHA1 (Table 1).
However, low HI titers and negative virus neutralization
were observed in sera derived from guinea pigs immu-
nized with the same dosage of detergent-solubilized
recombinant hemagglutinin protein.
Conclusion
These results show that recombinant hemagglutinin
expressed from baculovirus elicits an antibody response
in guinea pigs and induces HI and neutralization titers
against to the H5N1 avian influenza virus. Therefore, this
protein has good potential for use as antigen for subunit
vaccine and diagnostic test. This system coupled with sus-
pension culture could probably be easily adapted to large
scale manufacturing of H5 antigen for the development of
subunit vaccine and diagnostic test for H5 avian influenza
virus.
Methods
Influenza virus H5N1 and rabbit anti H5N1
A/goose/Guangdong/97 (H5N1) virus was obtained from
the allantoic fluid. Rabbits were injected intramuscularly
with 1 mg of purified H5N1 virus in Freund's complete
adjuvant (Sigma). Three successive injections were per-
formed with 2-week intervals. Blood samples were col-
lected 2 weeks after the last injection for serum
preparation.
Preparation of recombinant baculovirus
Influenza virus A/goose/Guangdong/97 (H5N1) was used
to inoculate 10-day-old specific-pathogen-free (SPF)
embryonated chicken eggs. Allantoic fluid containing the
virus was harvested at day 14 and inactivated with 0.4%
paraformaldehyde. RNA was extracted from the inacti-
vated virus using TRIzol reagent (Invitrogen) and the HA1
gene amplified by RT-PCR using HA1 forward (5'-
CGGGATCCGATGGAGAAAACAGTGCTTC-3') and
reverse (5'-ACGCGTCGACTTTCACATATTT-
GGGGCATTC-3') primers. The amplified HA1 DNA was
resolved on an agarose gel, purified (Qiaquick, Qiagen)
and sequenced and ligated to the pFastBac (Invitrogen)
donor vector. The resulting recombinant vector was intro-
Expression of rHA1 in baculovirus infected Sf9 cells under monolayer (A) and suspension (B) culture conditions Figure 3
Expression of rHA1 in baculovirus infected Sf9 cells under monolayer (A) and suspension (B) culture conditions. Each data 
point is the average from triplicate experiments and the error bars represent the 95% confidence level.
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duced into the target bacmid by homologous recombina-
tion as described in the pFastBac protocol.
Insect cell culture
Sf9 cells (Invitrogen) were transfected with recombinant
bacmid DNA and the recombinant baculovirus collected
from the culture medium at 72 h post-transfection as sug-
gested by the manufacturer. Cells were maintained in
monolayer cultures at 27°C. Cells were subcultured every
2 days by diluting seed cultures at 4.75 × 105 cells/ml to a
cell density of 2.38 × 105 cells/ml with fresh medium.
Transfection and recovery of recombinant baculovirus
from Sf9 cultures was performed according to the pFast-
Bac protocol (Invitrogen), and virus infectivity titer was
determined on sample supernatants using a modified
indirect immunofluorescence assay [24,25].
Expression of recombinant hemagglutinin in insect 
monolayer and suspension cultures
Sf9 cells were grown as monolayers at 27°C in 175 cm2
flasks using Sf900 II medium. Infection with recombinant
baculovirus was at a multiplicity of infection of 0.4 PFU/
cell using an initial cell density of 2.2 × 105 cells/ml. Cells
were harvested at various times postinfection. For suspen-
sion culture, cells were grown in 100 ml volumes in 500
ml baffled glass flasks and incubated in a rotary shaker at
80 rpm and 28°C. The initial cell density was 2.2 × 105
cells/ml. The cultures were infected with the recombinant
baculovirus with a multiplicity of infection of 0.4 PFU/
cell and cells harvested from the culture medium at vari-
ous times postinfection. Cells were harvested by centrifu-
gation at 3000 × g for 10 min and the resulting cell pellets
treated with Laemmli sample buffer prior to SDS-PAGE
on 12% gels. Hemagglutinin yields were estimated by
densitometric analysis [26,27] of stained gels following
electrophoresis with Quantity One software (Bio-Rad).
Spent culture medium was saved for determination of glu-
cose and secreted protein concentration.
Purification of rHA1
The infected cell pellets were washed once with sodium
phosphate buffer (pH 7.4) and then resuspended in lysis
buffer (50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 1% Ige-
pal CA-630) and sonicated in ice for 30 seconds. Soluble
and insoluble fractions were separated by centrifugation
for 15 min at 12,000 rpm, the insoluble pellet resus-
pended in Laemmli sample buffer and the proteins
resolved by SDS-PAGE. The band corresponding to the 35
kDa rHA1 protein was excised and the protein purified by
electroelution (Model 422 Electro-Eluter, Bio-Rad). Puri-
fied rHA1 was quantified using a Bradford protein assay
kit (Bio-Rad) prior to immunization of guinea pigs.
Immunoblotting
Estimation of molecular weight and binding properties of
hemagglutinin were determined by immunoblotting with
minor modifications of the method described by Caland-
rella et al [28]. First, proteins in each sample were sepa-
rated by 12% SDS-PAGE and followed by trans-blotting
onto nitrocellulose membrane (0.45 µm, Bio-Rad Labora-
tories, Singapore). The blotting was performed in transfer
buffer (25 mM Tris and 192 mM glycine in 20% metha-
nol) at 100 V for 60 min. After blotting, the membrane
was blocked by incubation in 3 % blocking solution (3 %
non-fat dry milk, 0.1 % Tween 20, 150 mM NaCl, 20 mM
Tris) for 1 h at room temperature. The blocked membrane
was incubated with rabbit H5N1 antiserum solution
(1:1000 v/v) for 1 h at room temperature and washed in
TBST (20 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20).
Subsequently, the membrane was incubated with goat
anti-rabbit IgG alkaline phosphatase conjugate (1:1000 v/
v, Sigma) for 1 h at room temperature. After three washes
with TBST, a substrate solution containing 20 ml of 0.1 M
Table 1: Antibody response of guinea pigs to recombinant 
hemagglutinin protein rHA1from influenza virus H5N1.
Protein HI titer Neutralization titer
rHA1 (insoluble) ≥ 1:160 ≥ 1:160
Denatured rHA1 < 1:20 < 1:10
Control < 1:10 < 1:10
SDS-PAGE and immunoblot analysis of supernatant (lane 1  and 3) and pellet (lane 2 and 4) after lysis of recombinant  baculovirus infected Sf9 cell with lysis buffer containing 1%  NP-40 Figure 4
SDS-PAGE and immunoblot analysis of supernatant (lane 1 
and 3) and pellet (lane 2 and 4) after lysis of recombinant 
baculovirus infected Sf9 cell with lysis buffer containing 1% 
NP-40. Values on the left indicate molecular weights of the 
maker protein (LaneM).BMC Microbiology 2006, 6:16 http://www.biomedcentral.com/1471-2180/6/16
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Tris-HCl, pH 7.4, 20 mg DAB, 10 µl of H2O2 was added.
After developing the band, the membrane was washed
with water to remove the substrate solution.
Determination of cell density, protein and glucose 
concentration in the culture medium
Cell density was determined by counting under a stereo
light microscope (Olympus, Japan) using a Neubaeur
haemocytometer (Weber, England). Triplicate counts
were carried out in each experiment. Dead cells were dis-
tinguished by Trypan Blue (Sigma-Aldrich, MO) uptake
[29].
Secreted protein concentration in the fermentation
medium was determined according to the method as
described by Bradford [30] using bovine serum albumin
(BSA) as the reference standard. Glucose concentration
was measured using Dygert method [31].
Immunolabelling of Sf9 cells and recombinant baculovirus 
infected Sf9 cells
Normal Sf9 cells and infected Sf9 cells were collected from
the suspension culture and allowed to attach in the 4
chamber slides at room temperature (RT) for 2 h. The cells
were then washed twice with PBS (pH 7.4) and fixed with
99 % absolute ethanol at RT for 30 min. Before immunos-
taining, cells were rinsed twice with PBS (pH 7.4). A
mouse monoclonal antibody specific to the HA1 protein
of H5 was produced (monoclonal antibody 4C12, our
unpublished data) and used to identify HA1 protein in
the cells. After incubation with monoclonal antibody
4C12, cells were washed several times in PBS (pH 7.4) and
visualized with the fluorescence isothiocynate-conjugated
anti-mouse antibody (DAKO, Denmark). After labelling,
cells were washed twice with PBS and the nuclei were
stained with DAPI (4,6-diamidino-2-phenylindole). Cells
were washed twice with PBS. Finally, cells were embedded
with 2–4 drops of immu-mount (Shandon, USA) and
cover slips were left for overnight at RT before examina-
tion with a laser scanning fluorescence microscope (Carl
Zeiss Laser Scanning Microscope, Axiovert 200 M,
LSM510META, Germany) with excitation and emission
settings appropriate for the dyes used.
Immunization of guinea pigs
Guinea pigs were supplied from The Centre for Animal
Resources at the National University of Singapore. Ani-
mals were approximately 4 months of age with an average
body weight of approximately 500 g. Two group of guinea
pigs were immunized with partially purified insoluble
rHA1 and purified denature rHA1 protein. Each group of
six guinea pigs was injected intramuscularly with 50 µg of
insoluble rHA1 protein homogenized in Freund's com-
plete adjuvant and 50 µg of purified denature rHA1 pro-
tein in Freund's complete adjuvant respectively. After two-
weeks they received another dose of 50 µg antigen in Fre-
und's complete adjuvant. Serum samples were taken two
weeks after the last injection. Sera were tested for neutral-
izing activity against H5N1 virus by using a microneutral-
ization assay [31] and hemagglutinin inhibition test (HI)
[32].
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